Engine Capital Reaches Agreement with PDL BioPharma for Board Representation and Governance Improvements

Firm News

Yahoo Finance, Reuters and other media sources reported on the agreement reached between Olshan client Engine Capital and PDL BioPharma pursuant to which Alan Bazaar was appointed to the company’s Board of Directors and as the Chairman of its newly-formed Cost Committee intended to oversee cost reduction initiatives. As part of the agreement, PDL BioPharma also agreed to present a proposal to declassify its Board at the upcoming 2020 annual meeting. Andrew Freedman and Ryan Nebel represent Engine Capital in connection with its investment in PDL BioPharma.

Media Contact

Marketing Contact
Mizi Mehaj
Marketing & Administrative Manager

Jump to Page

Necessary Cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Analytical Cookies

Analytical cookies help us improve our website by collecting and reporting information on its usage. We access and process information from these cookies at an aggregate level.